Login
Companies $RNTX
$0.38 -$0.02 (5.35%) After hours
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc.

reintx.com

What Do They Do?

Develops peptide and enzyme drug candidates for patients with pulmonary and fibrotic diseases, including idiopathic pulmonary fibrosis and loculated pleural effusion.

How Do They Make Money?

No revenue reported yet.

Who Are Their Customers?

It is developing drug candidates for people with idiopathic pulmonary fibrosis and loculated pleural effusion; it has no marketing, sales or distribution capabilities and may work with pharmaceutical and biotechnology companies to commercialize approved products.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▲ +1% (Loss)
vs −$5.6M in Q3 FY2025
  • Aug 21, 2026 Nasdaq notified Rein that its stock price fell below the minimum bid requirement Rein has until February 17, 2027, to regain compliance; otherwise Nasdaq may begin suspension and delisting procedures.

From cancer support to pulmonary fibrosis The older report centered on a peptide drug intended to protect cancer patients from chemotherapy side effects; the latest report centers on therapies for pulmonary and fibrotic diseases, led by a candidate for idiopathic pulmonary fibrosis.

Who Do They Compete With?

Competes with AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Avalyn Pharma, Vicore Pharma Holding, Endeavor BioMedicines, PureTech Health, and Roche Holding

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support